<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04103034</url>
  </required_header>
  <id_info>
    <org_study_id>BT200-01</org_study_id>
    <nct_id>NCT04103034</nct_id>
  </id_info>
  <brief_title>A SAD/MAD Study of Safety, Tolerability and Pharmacologic Activity of BT200 in Normal Volunteers</brief_title>
  <official_title>A Single/Multiple Ascending Dose Phase 1 Study of the Safety, Tolerability and Pharmacologic Activity of BT200 in Normal Human Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Band Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Band Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study BT200-01 is a first in human (FIH) study in male and female normal human volunteers
      (NHVs) that uses an Integrated Protocol Design. This Phase 1 study will comprise 4 sub-parts:
      Part A, a single ascending dose (SAD) study; Part B, a multiple ascending dose (MAD) study;
      Part C, a desmopressin challenge study to explore (i) whether desmopressin could be used as
      an antidote, and/or (ii) whether desmopressin stimulated vonWillebrand Factor (VWF) release
      is overcome with increasing BT200 doses; and Part D, a relative bioavailability (BA) study.

      The primary objective of this study is to assess the safety and tolerability profile of BT200
      in NHVs.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 7, 2019</start_date>
  <completion_date type="Anticipated">November 5, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 5, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>Baseline through 8 weeks after dosing</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measured concentration of BT200 at serial time points</measure>
    <time_frame>Baseline through 8 weeks after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measured Area Under the Curve (AUC)</measure>
    <time_frame>Baseline through 8 weeks after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration (Cmax)</measure>
    <time_frame>Baseline through 8 weeks after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum plasma concentration (Tmax)</measure>
    <time_frame>Baseline through 8 weeks after dosing</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Immunogenicity of BT200</measure>
    <time_frame>Baseline through 8 weeks after dosing</time_frame>
    <description>Evaluate the presence of anti-drug-antibodies against BT200</description>
  </other_outcome>
  <other_outcome>
    <measure>Assess VWF activity using ELISA for free VWF A1 Domains</measure>
    <time_frame>Baseline through 8 weeks after dosing</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Assess VWF function using Platelet Function Analyzer-100</measure>
    <time_frame>Baseline through 8 weeks after dosing</time_frame>
  </other_outcome>
  <number_of_arms>16</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Cerebrovascular Stroke</condition>
  <condition>Large-Artery Atherosclerosis (Embolus/Thrombosis)</condition>
  <condition>Intracranial Arteriosclerosis</condition>
  <arm_group>
    <arm_group_label>BT200 0.18mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a single subcutaneous dose of BT200 0.18mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BT200 0.6mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a single subcutaneous dose of BT200 0.6mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BT200 1.8mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a single subcutaneous dose of BT200 1.8mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BT200 6.0mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a single subcutaneous dose of BT200 6.0mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BT200 12.0mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a single subcutaneous dose of BT200 12.0mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BT200 24.0mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a single subcutaneous dose of BT200 24.0mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BT200 24.0mg repeat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a single subcutaneous dose of BT200 24.0mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo SAD</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive a single subcutaneous dose of placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BT200 loading dose 24.0mg, maintenance doses of 12.0 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive an initial subcutaneous loading doses of BT200 24.0mg followed by 4 weekly (every 7 days) maintenance doses of BT200 12.0mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BT200 loading doses 48.0mg, maintenance doses of 24.0 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive an initial subcutaneous loading dose of BT200 48mg followed by 4 weekly (every 7 days) maintenance doses of BT200 24mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo MAD</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive an initial subcutaneous loading dose of Placebo followed by 4 weekly (every 7 days) maintenance doses of placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BT200 48.0mg + desmopressin challenge</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a single subcutaneous dose of BT200 48.0mg followed by IV infusion (over 30 min) of 0.3µg/kg desmopressin administered 24 hours after single dose of BT200</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + desmopressin challenge dose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive a single subcutaneous dose of placebo followed by IV infusion (over 30 min of 0.3µg/kg desmopressin administered 24 hours after single dose of placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo infusion</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive a single IV dose of placebo administered over 24 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BT200 36.0mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a single subcutaneous dose of BT200 36.0mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BT200 48.0 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a single subcutaneous dose of BT200 48.0mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BT200</intervention_name>
    <description>BT200 is a PEGylated synthetic RNA oligonucleotide</description>
    <arm_group_label>BT200 0.18mg</arm_group_label>
    <arm_group_label>BT200 0.6mg</arm_group_label>
    <arm_group_label>BT200 1.8mg</arm_group_label>
    <arm_group_label>BT200 12.0mg</arm_group_label>
    <arm_group_label>BT200 24.0mg</arm_group_label>
    <arm_group_label>BT200 24.0mg repeat</arm_group_label>
    <arm_group_label>BT200 36.0mg</arm_group_label>
    <arm_group_label>BT200 48.0 mg</arm_group_label>
    <arm_group_label>BT200 48.0mg + desmopressin challenge</arm_group_label>
    <arm_group_label>BT200 6.0mg</arm_group_label>
    <arm_group_label>BT200 loading dose 24.0mg, maintenance doses of 12.0 mg</arm_group_label>
    <arm_group_label>BT200 loading doses 48.0mg, maintenance doses of 24.0 mg</arm_group_label>
    <arm_group_label>Placebo + desmopressin challenge dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Desmopressin</intervention_name>
    <description>Sterile solution for injection</description>
    <arm_group_label>BT200 48.0mg + desmopressin challenge</arm_group_label>
    <arm_group_label>Placebo + desmopressin challenge dose</arm_group_label>
    <other_name>MINIRIN® Injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Sterile saline for injection</description>
    <arm_group_label>Placebo MAD</arm_group_label>
    <arm_group_label>Placebo SAD</arm_group_label>
    <arm_group_label>Placebo infusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy male or female volunteers, age ≥ 18 years old at screening

          2. If female, must be post-menopausal or status post hysterectomy

          3. Able to comprehend and to give informed consent

          4. Able to cooperate with the Investigator, to comply with the requirements of the study,
             and to complete the full sequence of protocol-related procedures

        Exclusion Criteria:

          1. Clinically significant medical history (including von Willebrand Disease,
             thrombocytopathy, or any type of bleeding diathesis) or ongoing chronic illness that
             would jeopardize the safety of the subject or compromise the quality of the data
             derived from his/her participation in this study

          2. Clinically relevant abnormal findings on physical examination or clinically relevant
             laboratory abnormalities

          3. History of infusion hypersensitivity reactions, significant drug allergy, or
             anaphylactic reactions

          4. Substance abuse, mental illness, or any reason that makes it unlikely in the judgment
             of the Investigator for the subject to be able to comply fully with study procedures

          5. Use of medication during 2 weeks before the start of the study, which in the judgment
             of the Investigator may adversely affect the subject's welfare or the integrity of the
             study's results

          6. Concurrent treatment with other experimental drugs or participation in another
             clinical trial with any investigational drug within 30 days or 5 elimination
             half-lives (whichever is longer) prior to treatment start
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James C Gilbert, MD</last_name>
    <role>Study Director</role>
    <affiliation>Band Therapeutics</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ulla Derhaschnig, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Vienna</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <reference>
    <citation>Buchtele N, Schwameis M, Gilbert JC, Schörgenhofer C, Jilma B. Targeting von Willebrand Factor in Ischaemic Stroke: Focus on Clinical Evidence. Thromb Haemost. 2018 Jun;118(6):959-978. doi: 10.1055/s-0038-1648251. Epub 2018 May 30. Review.</citation>
    <PMID>29847840</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>September 19, 2019</study_first_submitted>
  <study_first_submitted_qc>September 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 25, 2019</study_first_posted>
  <last_update_submitted>July 10, 2020</last_update_submitted>
  <last_update_submitted_qc>July 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Secondary Stroke Prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Intracranial Arteriosclerosis</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Arteriosclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Deamino Arginine Vasopressin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

